These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 31911277)
1. Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway. Fu Y; Wang Z; Luo C; Wang Y; Wang Y; Zhong X; Zheng H Transl Oncol; 2020 Feb; 13(2):423-440. PubMed ID: 31911277 [TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4. Lu H; Sun J; Wang F; Feng L; Ma Y; Shen Q; Jiang Z; Sun X; Wang X; Jin H Cell Death Dis; 2013 Aug; 4(8):e776. PubMed ID: 23949225 [TBL] [Abstract][Full Text] [Related]
3. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway. Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766 [TBL] [Abstract][Full Text] [Related]
4. CXXC4 mediates glucose-induced β-cell proliferation. Guan B; Zhan Z; Wang L; Wang L; Liu L Acta Diabetol; 2020 Sep; 57(9):1101-1109. PubMed ID: 32280999 [TBL] [Abstract][Full Text] [Related]
5. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439 [TBL] [Abstract][Full Text] [Related]
6. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Kojima T; Shimazui T; Hinotsu S; Joraku A; Oikawa T; Kawai K; Horie R; Suzuki H; Nagashima R; Yoshikawa K; Michiue T; Asashima M; Akaza H; Uchida K Oncogene; 2009 Jan; 28(2):297-305. PubMed ID: 18931698 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line. Won HS; Lee KM; Oh JE; Nam EM; Lee KE PLoS One; 2016; 11(5):e0155983. PubMed ID: 27196739 [TBL] [Abstract][Full Text] [Related]
8. Vitamin D-induced vitamin D receptor expression induces tamoxifen sensitivity in MCF-7 stem cells via suppression of Wnt/β-catenin signaling. Zheng W; Duan B; Zhang Q; Ouyang L; Peng W; Qian F; Wang Y; Huang S Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30314996 [No Abstract] [Full Text] [Related]
9. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells. Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368 [TBL] [Abstract][Full Text] [Related]
10. Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers. Leung EY; Askarian-Amiri ME; Sarkar D; Ferraro-Peyret C; Joseph WR; Finlay GJ; Baguley BC Front Oncol; 2017; 7():184. PubMed ID: 28929082 [TBL] [Abstract][Full Text] [Related]
11. New tumor suppressor CXXC finger protein 4 inactivates mitogen activated protein kinase signaling. Lu H; Jin W; Sun J; Feng L; Lan H; Shen Q; Ma Y; Li J; Yue Y; Jin H; Wang X FEBS Lett; 2014 Sep; 588(18):3322-6. PubMed ID: 25064842 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/β-catenin signaling pathway. Jiang Q; He M; Guan S; Ma M; Wu H; Yu Z; Jiang L; Wang Y; Zong X; Jin F; Wei M Tumour Biol; 2016 Apr; 37(4):5001-11. PubMed ID: 26537584 [TBL] [Abstract][Full Text] [Related]
13. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289 [TBL] [Abstract][Full Text] [Related]
14. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165 [TBL] [Abstract][Full Text] [Related]
15. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
16. Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer. Sakunrangsit N; Ketchart W Pharmacol Res; 2019 Dec; 150():104517. PubMed ID: 31693936 [TBL] [Abstract][Full Text] [Related]
17. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression. Yu J; Liu D; Sun X; Yang K; Yao J; Cheng C; Wang C; Zheng J Cell Death Dis; 2019 Jan; 10(1):26. PubMed ID: 30631044 [TBL] [Abstract][Full Text] [Related]
18. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472 [TBL] [Abstract][Full Text] [Related]
19. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma. Chen Q; Zheng PS; Yang WT Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879 [TBL] [Abstract][Full Text] [Related]
20. Dermatopontin inhibits WNT signaling pathway via CXXC finger protein 4 in hepatocellular carcinoma. Liu S; Qiu J; He G; Geng C; He W; Liu C; Cai D; Pan H; Tian Q J Cancer; 2020; 11(21):6288-6298. PubMed ID: 33033513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]